Table 4 The summary of macrophage associated NDDS in several diseases
From: Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
NDDS name | Agent | Target/Drug category | Combination therapy | Mechanism | Disease | References |
|---|---|---|---|---|---|---|
pIL-12 + PLX@cR-PssPD | PLX3397(PLX) | CSF-1R inhibition | pIL-12 | The promotion of the TAMs repolarization | Melanoma and colon cancer | |
/ | CSF-1R siRNA | CSF-1R inhibition | / | The promotion of the TAMs repolarization | Prostate cancer | |
CCR2-MM@PLGA/Cur | CCR2 overexpression on the MM | trapping CCL2 | / | The reduction of macrophage infiltration and microglia pro-inflammatory polarization | Spinal cord injury (SCI) | |
MSN@CS/HA | Hydrogen molecules | increased CCL2 expression | / | The promotion of the anti-inflammatory M2-type polarization | Burn skin wounds | |
BBLZ-945@PAC-PTX | BBLZ-945 | CSF-1R inhibition | / | The depletion of TAMs | Melanoma and breast cancer | |
| Â | PBA-pAMD-Cholesterol (PAC) | CXCR4 blockade | / | The reduction of macrophage recruitment | Â | Â |
/ | CXCR4 overexpression on the MSCs | The neutralization of CXCL12 | / | The inhibition of mononuclear macrophages infiltration | Ischemic stroke | |
| Â | A151 | cGAS inhibition | / | The promotion of the microglia M2-type polarization via inhibiting cGAS-STING pathway | Â | Â |
CV-S NPs | Valproic acid(VPA) | HDAC inhibitor | / | The suppression of the TLR4-MyD88-NF-κB signaling and TNF-α secretion of macrophages | Inflammation | |
PLGA-ION-R837@M | Imiquimod (R837) | TLR7 agonist | Fe3O4 NPs | The promotion of the TAMs repolarization | Breast cancer | |
D&R-HM-MCA | Resiquimod(R848) | TLR7/8 agonist | / | The promotion of the TAMs repolarization | Glioblastoma | |
NAcp@CD47 | Anti-CD47 antibodies | CD47 blockade | Cyclic di-GMP(CDG) | The promotion of macrophages/microglia phagocytosis and TAMs M1-type polarization | Glioblastoma | |
/ | TTA-Q6 | T-type calcium channel inhibitor | / | The promotion of antigen presentation by activating macrophages | Lung cancer | |
| Â | RRX-001 | CD47 inhibitor | / | The promotion of macrophages phagocytosis | Â | Â |
MPIRx | RRX-001 | CD47 inhibitor | IR780 | The promotion of phagocytosis and M1-type polarization of macrophages | Osteosarcoma | |
/ | RP-182 | CD206 activation | / | The activation of phagocytosis and autophagy as well as promotion of the M2-type macrophage repolarization | Brainstem glioma | |
| Â | Â | Â | / | Â | Â | |
siCD40/NPs | CD40 siRNA | CD40 blockade | / | The depletion of macrophages and inhibition of macrophage differentiation | Alloimmune responses in skin allotransplantation | |
/ | IPI-549 | PI3Kγ inhibitor | Photosensitizer chlorin e6 (Ce6) | The reduction of M2-type TAMs infiltration into tumors | Colon cancer | |
Nano-PI | IPI-549 | PI3Kγ inhibitor | Paclitaxel (PTX) | The promotion of M2-type macrophages repolarization | Breast cancer | |
HN-HFPA | L-norvaline (L-Nor) | Arg-1 inhibitor | / | The increase of M1-type macrophages ratio in tumor | Triple negative breast cancer (TNBC) | |
n-PN/p-LP@aero-μGel | Imatinib | Tyrosine Kinase Inhibitors (TKI) | / | The promotion of M1-type macrophage polarization and inhibition of M2-type macrophage polarization | Candida albicans Infection | |
GBZ-Loaded Lipo-NPs | Guanabenz(GBZ) | Alpha-2(α2) adrenergic receptor agonist | / | The reduction of TLR4-induced inflammatory cytokines secretion by macrophages | Inflammation | |
lipoprodrug | Cabazitaxel | Taxanes | / | The promotion of proinflammatory macrophage polarization | Melanoma | |
Ncl-NPs | Niclosamide (Ncl) | Anthelmintic | / | The inhibition of M2-type macrophage polarization | Pulmonary fibrosis |
